Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002578 · ClinicalTrials.gov registry record · Phase 2
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 3
- Study locations
NCT00002578 is a Phase 2 study of Lymphoma that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 35 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00002578, a Phase 2 study of Lymphoma, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG leucovorin calcium
- DRUG methotrexate
- DRUG cytarabine
- DRUG gallium nitrate
Study Locations (3)
New York
- Roswell Park Cancer Institute - Buffalo
- Albert Einstein Comprehensive Cancer Center - The Bronx
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1994-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002578
The ClinicalTrials.gov registry entry for NCT00002578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which leucovorin calcium is the first listed.
NCT00002578 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, California.
Frequently Asked Questions
What is clinical trial NCT00002578 about?
NCT00002578 is a clinical study titled "Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma". RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma.
What is the current status of trial NCT00002578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1994-08.
What conditions does trial NCT00002578 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00002578?
The interventions under investigation include: leucovorin calcium (DRUG), methotrexate (DRUG), cytarabine (DRUG), gallium nitrate (DRUG).
Who is sponsoring clinical trial NCT00002578?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002578 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.